PD-1单抗Libtayo-话题@MedSci

#PD-1单抗Libtayo#

4篇内容 | 577人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2005544, encodeId=3f342005544b4, content=<a href='/topic/show?id=0e40139082d' target=_blank style='color:#2F92EE;'>#PD-1单抗Libtayo#</a>, objectTitle=赛诺菲/再生元的PD-1单抗Libtayo在基底细胞癌中显示出明显益处, objectType=article, longId=193623, objectId=35ce1936233b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35ce1936233b, replyNumber=0, likeNumber=32, createdTime=2021-02-28, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35ce1936233b, moduleTitle=赛诺菲/再生元的PD-1单抗Libtayo在基底细胞癌中显示出明显益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35ce1936233b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2005543, encodeId=aca020055433f, content=<a href='/topic/show?id=0e40139082d' target=_blank style='color:#2F92EE;'>#PD-1单抗Libtayo#</a>, objectTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, objectType=article, longId=174938, objectId=c1da1e4938eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e4938eb, replyNumber=0, likeNumber=39, createdTime=2020-04-18, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e4938eb, moduleTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e4938eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2005542, encodeId=499a2005542d4, content=<a href='/topic/show?id=0e40139082d' target=_blank style='color:#2F92EE;'>#PD-1单抗Libtayo#</a>, objectTitle=欧盟批准赛诺菲的PD-1单抗Libtayo用于治疗皮肤癌, objectType=article, longId=174726, objectId=564d1e472602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=564d1e472602, replyNumber=0, likeNumber=36, createdTime=2019-11-23, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=564d1e472602, moduleTitle=欧盟批准赛诺菲的PD-1单抗Libtayo用于治疗皮肤癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=564d1e472602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2005541, encodeId=675f200554199, content=<a href='/topic/show?id=0e40139082d' target=_blank style='color:#2F92EE;'>#PD-1单抗Libtayo#</a>, objectTitle=FDA批准赛诺菲和再生元的PD-1单抗Libtayo用于治疗晚期皮肤鳞状细胞癌, objectType=article, longId=150020, objectId=3d9e15002092, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d9e15002092, replyNumber=0, likeNumber=25, createdTime=2019-04-09, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d9e15002092, moduleTitle=FDA批准赛诺菲和再生元的PD-1单抗Libtayo用于治疗晚期皮肤鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d9e15002092)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1单抗Libtayo

2020-05-29

gujh (审核中...)

前往app查看评论内容

#PD-1单抗Libtayo#

赛诺菲/再生元的PD-1单抗Libtayo在基底细胞癌中显示出明显益处

2021-02-28

gujh (审核中...)

前往app查看评论内容

#PD-1单抗Libtayo#

英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌

2020-04-18

gujh (审核中...)

前往app查看评论内容

#PD-1单抗Libtayo#

欧盟批准赛诺菲的PD-1单抗Libtayo用于治疗皮肤癌

2019-11-23

gujh (审核中...)

前往app查看评论内容

#PD-1单抗Libtayo#

FDA批准赛诺菲和再生元的PD-1单抗Libtayo用于治疗晚期皮肤鳞状细胞癌

2019-04-09

科室
- - 订阅+
  - 更多科室
工具
服务